SCHEMBL16626939

SCHEMBL16626939

CC(C)(C)OC(=O)NCCc1ccc(NC(=O)CCl)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAMPT P43490 2/20 0.61
CA2 P00918 3/20 0.53
CA1 P00915 2/20 0.53
CNR1 P21554 4/20 0.48
FPR2 P25090 1/20 0.45
CYP17A1 P05093 1/20 0.45
HTT P42858 2/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
MITF O75030 2/20 0.44
PTPN11 Q06124 1/20 0.44
XBP1 P17861 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
NOD2 Q9HC29 1/20 0.44
IGF1R P08069 1/20 0.44
LMNA P02545 1/20 0.44
HPGD P15428 1/20 0.44
RNF4 P78317 1/20 0.43
PRMT1 Q99873 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19889032 0.89 NAMPT (0.61) NAMPTCA2CA1CNR1CYP17A1
SCHEMBL19889037 0.88 NAMPT (0.60) NAMPTCA2CA1CNR1FPR2
SCHEMBL19889238 0.88 NAMPT (0.60) NAMPTCA2CA1CNR1CYP17A1
SCHEMBL23963303 0.86 NAMPT (0.57) NAMPTCA2CA1CNR1CYP17A1
SCHEMBL16193024 0.85 NAMPT (0.62) NAMPTCA2CA1CYP17A1HTT
SCHEMBL1438420 0.84 NPC1 (0.53) NAMPTCA2CA1CYP17A1HTT
SCHEMBL2728636 0.84 NAMPT (0.55) NAMPTCA2CA1CNR1IGF1R
SCHEMBL27478755 0.83 NAMPT (0.57) NAMPTCA2CA1CNR1NPC1
SCHEMBL7015585 0.83 NAMPT (0.59) NAMPTCA2CA1CYP17A1NPC1
SCHEMBL23291267 0.83 CYP17A1 (0.57) NAMPTCA2CA1CYP17A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118108709-B Preparation method and application of target CDK19 radionuclide labeling reagent 中国医学科学院放射医学研究所 2026-05-19 CN disclosed
US-10227327-B2 Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety Universitetet | Oslo (NO) 2019-03-12 US disclosed
EP-3052135-B1 INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY UNIV OSLO (NO) 2018-07-18 EP disclosed
US-20160244431-A1 Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety UNIVERSITETET I OSLO (NO) 2016-08-25 US disclosed
US-20160244431-A1 Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety UNIVERSITETET I OSLO (NO) 2016-08-25 US disclosed
WO-2015049546-A1 INHIBITORS OF METALLO-BETA-LACTAMASE (MBL) COMPRISING A ZINC CHELATING MOIETY UNIVERSITETET I OSLO (NO) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160244431-A1 Inhibitors of Metallo-Beta-Lactamase (MBL) Comprising a Zinc Chelating Moiety SLC30A6, DDO, SLC30A7 NAMPT 583/4885CA2 2702/4885CA1 2957/4885
US-10227327-B2 Inhibitors of metallo-beta-lactamase (MBL) comprising a zinc chelating moiety SLC30A6, DDO, SLC30A7 NAMPT 583/4885CA2 2702/4885CA1 2957/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.